Recent advancements of bortezomib in acute lymphocytic leukemia treatment.

@article{Du2013RecentAO,
  title={Recent advancements of bortezomib in acute lymphocytic leukemia treatment.},
  author={Xiao-li Du and Qian Chen},
  journal={Acta haematologica},
  year={2013},
  volume={129 4},
  pages={207-14}
}
Although survival rates for acute lymphocytic leukemia (ALL), especially in children, have shown dramatic improvement over time, poor outcomes are still observed in patients who have refractory or relapsed disease after conventional chemotherapy. New therapeutic options are urgently needed. Bortezomib (Velcade, formerly PS-341) is the first proteasome inhibitor approved by the US FDA for the treatment of newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma and mantle cell… CONTINUE READING
5 Citations
50 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Similar Papers

Loading similar papers…